Enanta Pharmaceuticals INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
SCHEDULE 13D/A: Enanta Pharmaceuticals CEO Boosts Stake with Open Market Purchase and Performance-Based Equity
Enanta Pharmaceuticals, Inc. CEO, Dr. Jay R. Luly, has increased his beneficial ownership to 7.7% through a recent open market share purchase and the vesting of performance share units.